LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY

Purpose: To evaluate long-term efficacy and safety of ranibizumab for treatment of myopic choroidal neovascularization (mCNV) in clinical practice. Methods: Noninterventional, retrospective cohort study of East-Asian patients previously treated with ranibizumab during the RADIANCE trial. Forty-one patients who completed the RADIANCE trial were followed-up for up to 48 months (post-RADIANCE observation period). Outcome measures were best-corrected visual acuity changes from baseline (assessed at RADIANCE trial initiation), mCNV recurrences, and ocular adverse events. Results: Mean visual gain from baseline best-corrected visual acuity (56.5 +/- 12.1 letters) (20/80) was significant at 12 months (+ 14.3 +/- 11.4 letters, n = 40, P < 0.0001), 24 months (+10.4 +/- 22.3 letters, n = 31, P = 0.0143), 30 months (+11.0 +/- 22.4 letters, n = 29, P = 0.0134), 42 months (+12.9 +/- 20.9 letters, n = 25, P = 0.0051), and 48 months (+16.3 +/- 18.7, n = 16, P = 0.0034). Of the 16 patients who completed 48 months of follow-up, 63% gained >= 10 letters and 13% lost >= 10 letters. Over the post-RADIANCE observation period, 83% of patients required no further treatment for mCNV, 10% experienced mCNV recurrences, and 12% experienced a nonserious ocular adverse event. Patients who required additional treatment for mCNV received a mean of 5.0 (SD 5.9, range 1.0-18.0) ranibizumab injections. Conclusion: Best-corrected visual acuity gained at the end of the RADIANCE trial was sustained over additional 36 months of follow-up. Few patients required further treatment and no new safety concerns were observed.